Generation of CAR-TSCM: CAR-T with super clutch
- PMID: 38833844
- DOI: 10.1016/j.intimp.2024.112379
Generation of CAR-TSCM: CAR-T with super clutch
Abstract
CAR-T therapy has demonstrated effectiveness in hematological malignancies and is now striding into solid tumor areas. One of the main roadblocks of CAR-T therapy is T cell exhaustion normally aroused by T cell terminal differentiation due to persistent contact with antigen in vivo or in vitro manufacturing process. TSCM positions as the first, and pivotal step of naïve T cell differentiation to downstream memory and effector stages. Researchers highly seek to restrain CAR-T cells at the TSCM stage during manufacture as TSCM percentage in CAR-T products is strongly associated with better treatment response. We reviewed the recent strategies regarding CAR-TSCM generation from aspects of starting source, manufacturing process, CAR assembly, transcription factor and metabolism regulation, etc.
Keywords: CAR; CAR-T; CAR-T(SCM); T stem cell like memory; T(SCM).
Copyright © 2024 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Efficient derivation of chimeric-antigen receptor-modified TSCM cells.Front Immunol. 2022 Jul 28;13:877682. doi: 10.3389/fimmu.2022.877682. eCollection 2022. Front Immunol. 2022. PMID: 35967430 Free PMC article.
-
A multi-kinase inhibitor screen identifies inhibitors preserving stem-cell-like chimeric antigen receptor T cells.Nat Immunol. 2025 Feb;26(2):279-293. doi: 10.1038/s41590-024-02042-1. Epub 2025 Jan 8. Nat Immunol. 2025. PMID: 39779871 Free PMC article.
-
Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients.Front Immunol. 2020 Jun 19;11:1217. doi: 10.3389/fimmu.2020.01217. eCollection 2020. Front Immunol. 2020. PMID: 32636841 Free PMC article.
-
Strategies for Altering Delivery Technologies to Optimize CAR Therapy.Int J Mol Sci. 2025 Mar 30;26(7):3206. doi: 10.3390/ijms26073206. Int J Mol Sci. 2025. PMID: 40244018 Free PMC article. Review.
-
Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003. Curr Res Transl Med. 2017. PMID: 28988742 Review.
Cited by
-
Immune Memory: A New Frontier in Treating Recurrent Inflammatory Skin Diseases.Clin Rev Allergy Immunol. 2025 Mar 18;68(1):31. doi: 10.1007/s12016-025-09039-0. Clin Rev Allergy Immunol. 2025. PMID: 40100550 Review.
-
Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies.Front Immunol. 2024 Nov 13;15:1490911. doi: 10.3389/fimmu.2024.1490911. eCollection 2024. Front Immunol. 2024. PMID: 39606234 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources